Precision Medicine Software Market Report 2026

The precision medicine software market size has grown rapidly in recent years. It will grow from $2.45 billion in 2025 to $2.82 billion in 2026 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to advancements in genomic sequencing technologies, expansion of electronic health record adoption, increasing use of data-driven clinical workflows, rising oncology-focused precision treatments, growing availability of bioinformatics platforms.

The precision medicine software market size is expected to see rapid growth in the next few years. It will grow to $4.92 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing demand for personalized therapeutics, rising investments in precision oncology programs, expansion of ai-enabled healthcare analytics, growing adoption of cloud-based clinical platforms, increasing focus on outcome-based healthcare models. Major trends in the forecast period include increasing adoption of AI-driven clinical decision support, rising integration of genomic and clinical data platforms, growing use of cloud-based precision medicine software, expansion of real-time patient data analytics, enhanced focus on interoperable healthcare systems.

The growing demand for personalized treatment is expected to drive the growth of the precision medicine software market in the coming years. Personalized treatment involves tailoring medical care to an individual’s specific genetic profile, lifestyle, and health history to achieve more effective outcomes. This rising demand is fueled by advances in genomic technologies, which allow precise identification of genetic variations and the development of tailored treatments. Precision medicine software supports personalized treatment by analyzing genetic, clinical, and lifestyle data to guide healthcare decisions. It improves diagnostic accuracy and treatment efficacy, enabling more targeted and efficient patient care. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 approvals in 2022. Consequently, the increasing demand for personalized treatment is driving the growth of the precision medicine software market.

Key companies in the precision medicine software market are focusing on developing advanced solutions, such as digital healthcare platforms, to streamline the creation of digital health products while reducing time and costs. Digital healthcare refers to the application of digital tools and technologies to deliver, manage, and enhance healthcare services and outcomes. For instance, in July 2024, Huma Therapeutics Ltd., a UK-based digital health company, launched its Cloud Platform, designed to democratize digital-first healthcare by enabling rapid, no-code creation and deployment of regulated health applications powered by artificial intelligence (AI). The platform includes pre-built components, integrates with medical devices, and complies with key regulatory standards (FDA Class II, EU MDR IIb, Saudi FDA C), allowing organizations of any size to deliver cost-effective and efficient digital health solutions. The Huma Cloud Platform accelerates digital health innovation, expands access, and supports proactive, AI-driven care and research.

In January 2023, QuartzBio, part of Precision for Medicine, a US-based bioinformatics company, acquired SolveBio Inc. for an undisclosed amount. Through this acquisition, Precision for Medicine aims to strengthen QuartzBio’s software-as-a-service (SaaS) capabilities by integrating SolveBio’s enterprise data management platform, enabling streamlined management of clinical samples and biomarker data across the drug development lifecycle. SolveBio Inc. is a US-based data integration and analysis company specializing in genomic and clinical data solutions for precision medicine.

Major companies operating in the precision medicine software market are Koninklijke Philips N.V., Palantir Technologies Inc., Tempus Labs Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Color Genomics Inc., NantHealth Inc., SOPHiA GENETICS SA, Aignostics GmbH, MVision AI Oy, Fabric Genomics Inc., QUIBIM S.L., Syapse Inc., PierianDx Inc., 2bPrecise LLC, SimBioSys Inc., Navignostics AG, xCures Inc., LifeOmic Holdings LLC.

North America was the largest region in the precision medicine software market in 2025. The regions covered in the precision medicine software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the precision medicine software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the precision medicine software market by increasing costs associated with imported data servers, specialized computing hardware, genomic analysis tools, and advanced IT infrastructure components. Healthcare providers and research institutions in North America and Europe are most affected due to reliance on high-performance imported hardware, while Asia-Pacific faces cost pressures in scaling cloud-based genomic platforms. These tariffs are raising deployment and maintenance costs for precision medicine solutions. However, they are also encouraging local data center investments, domestic software development, and regional partnerships that strengthen long-term digital health infrastructure.

The precision medicine software market research report is one of a series of new reports that provides precision medicine software market statistics, including precision medicine software industry global market size, regional shares, competitors with a precision medicine software market share, detailed precision medicine software market segments, market trends and opportunities, and any further data you may need to thrive in the precision medicine software industry. This precision medicine software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Precision medicine software refers to specialized digital platforms that analyze individual patient data - including genetic, molecular, clinical, and lifestyle information - to develop personalized treatment and prevention strategies. Its primary goal is to assist clinicians in making data-driven decisions that optimize therapeutic outcomes based on a patient’s unique biological profile.

The main categories of precision medicine software include clinical decision support systems (CDSS), genomic data analysis tools, data integration and management software, patient management software, and bioinformatics tools. Clinical decision support systems are health information technology solutions designed to help healthcare professionals make informed clinical decisions by providing evidence-based knowledge, patient-specific data, and treatment recommendations at the point of care. These systems utilize technologies such as artificial intelligence and machine learning, big data analytics, blockchain, the Internet of Medical Things (IoMT), and CRISPR and gene-editing tools, and can be deployed on cloud-based or on-premises infrastructures. They are applied across a variety of areas, including oncology, central nervous system disorders, immunology, cardiovascular diseases, and more, serving end users such as healthcare providers, research institutions, government agencies, pharmaceutical companies, and biotechnology firms.

The precision medicine software market consists of revenues earned by entities by providing services such as biomarker identification, patient stratification, treatment planning, data integration from electronic health records (EHRs), and laboratory information systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision medicine software market also consists of sales of clinical analytics platforms, genomic interpretation tools, bioinformatics software, and AI-driven diagnostic solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.